Shots: Gilead has exercised its options to 3 programs in Arcus’s portfolio, including both anti-TIGIT molecules, domvanalimab & AB308 along with etrumadenant & quemliclustat & will hold exclusive rights outside […]readmore
Shots: Under the existing collaboration agreement, Takeda has exercised an option to co-develop and co-commercialize DNL593 (PTV: PGRN) as brain-penetrant progranulin replacement therapy for the treatment of FTD-GRN In Jan […]readmore
Shots: The companies launch Semglee and Insulin Glargine as interchangeable biosimilars products to improve patients’ access with type 1 & 2 diabetes. Biocon and Viatris have co-developed both biosimilars products […]readmore
Shots: Gaeta to receive $0.2M up front and is eligible to receive ~$7.5M in clinical and regulatory milestones based on product and indication The agreement will expand Oncorus’ clinical development […]readmore
Shots: I-Mab to receive ~$35M up front & ~0.27M upon achievement of development, registration & sales milestones, $315M non-royalty payment & is eligible to receive royalties. The companies will share […]readmore
Shots: Novome to receive $15M up front & is also eligible to receive ~$590M in milestone upon the achievement of prespecified development and commercial milestones along with royalties on sales […]readmore
Shots: Karuna to receive $35M up front, ~$80M in development and regulatory milestones and is also eligible to receive ~$72M in sales milestones along with royalties based on sales of […]readmore
Shots: Blueprint will receive $25M up front, ~$590M in milestones along with royalties on net sales of BLU-945 & BLU-701 in Greater China & will retain all rights to BLU-945 […]readmore
Shots: Biohavem to receive $500M up front that consists of $150M cash & $350M in the purchase of Biohaven equity at a premium of 25% & are also eligible to […]readmore
Shots: Kronos will receive access to Tempus’ real-world data & tools to expand its preclinical/clinical development portfolio & retains an option to join Tempus’ TIME trial network to support patient […]readmore